Related Experiment Video
Updated: Jul 14, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
The transcription factor Wilms tumor 1 regulates matrix metalloproteinase-9 through a nitric oxide-mediated pathway
Marcelo Marcet-Palacios1, Marina Ulanova, Florentina Duta
1Glaxo-Heritage Asthma Research Laboraotries, Heritage Medical Research Center, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
Matrix metalloproteinase-9 (MMP-9) is released by human lung epithelial cells (LEC) in conditions such as asthma and chronic obstructive pulmonary disease and expression of MMP-9 correlates with the severity of these disorders. MMP-9 production has been reported to be regulated by a NO/soluble guanylate cyclase-dependent pathway. Transcriptional regulation of this enzyme, however, is poorly understood. Using phylogenetic analysis, we observed a highly conserved sequence in the 5' flanking region of the MMP-9 gene containing binding sites for the transcription factor Wilms tumor 1 (WT1). We confirmed the presence of WT1 in human LEC and that treatment with TNF or a mixture containing LPS, PMA, and IFN-gamma resulted in translocation of WT1 from the nucleus to the cytosol. This translocation coincided with increased expression of MMP-9 and could be blocked by inhibitors of the NO/soluble guanylate cyclase pathway. WT1 knockdown using small-interfering RNA up-regulated MMP-9 expression in the presence of the NO synthase inhibitor 1400W. Using either WT1 pulldown with probes for the conserved region of the MMP-9 promoter or chromatin immunoprecipitation, we confirmed WT1 binding to the MMP-9 promoter. These findings indicate WT1 is a repressor of MMP-9, regulated by a NO-mediated pathway in human LEC. To our knowledge, this is the first report of WT1 regulating MMP-9 expression. Further study is needed to determine whether clinical conditions exhibiting tissue remodeling, such as asthma and/or chronic obstructive pulmonary disease, demonstrate reduced levels of WT1 or its repressor activity.
Insights
Wilms tumor 1 (WT1) acts as a repressor of matrix metalloproteinase-9 (MMP-9) in human lung cells. This regulation is mediated by a nitric oxide (NO)-dependent pathway, impacting MMP-9 expression in lung diseases.
Area of Science:
- Molecular Biology
- Pulmonary Medicine
- Cellular Signaling
Background:
- Matrix metalloproteinase-9 (MMP-9) expression in human lung epithelial cells (LEC) is linked to respiratory diseases like asthma and COPD.
- While MMP-9 production is known to be modulated by NO/soluble guanylate cyclase pathways, its transcriptional regulation remains unclear.
- Wilms tumor 1 (WT1) is a transcription factor with a conserved binding site in the MMP-9 gene's 5' flanking region.
Purpose of the Study:
- To investigate the role of Wilms tumor 1 (WT1) in the transcriptional regulation of matrix metalloproteinase-9 (MMP-9) in human lung epithelial cells (LEC).
- To elucidate the involvement of the NO/soluble guanylate cyclase pathway in the regulation of WT1's activity concerning MMP-9 expression.
Main Methods:
- Phylogenetic analysis to identify conserved sequences in the MMP-9 gene promoter.
- Detection of WT1 in LEC and assessment of its subcellular localization upon stimulation with TNF or LPS/PMA/IFN-gamma.
- WT1 knockdown using siRNA and assessment of MMP-9 expression.
- Inhibition of the NO/soluble guanylate cyclase pathway.
- WT1 pulldown assays and chromatin immunoprecipitation (ChIP) to confirm WT1 binding to the MMP-9 promoter.
Main Results:
- WT1 was confirmed to be present in human LEC and its translocation from the nucleus to the cytosol was observed upon stimulation.
- This WT1 translocation correlated with increased MMP-9 expression and could be inhibited by NO/soluble guanylate cyclase pathway inhibitors.
- WT1 knockdown led to increased MMP-9 expression, and WT1 was confirmed to bind to the MMP-9 promoter, indicating a repressor role.
Conclusions:
- WT1 functions as a repressor of MMP-9 expression in human LEC, regulated by a NO-mediated pathway.
- This study is the first to report WT1's regulation of MMP-9.
- Further research is warranted to explore the potential role of reduced WT1 levels or activity in diseases characterized by tissue remodeling, such as asthma and COPD.
Related Concept Videos
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Role of Matrix Metalloproteases in Degradation of ECM
A...